猪细小病毒氢氧化铝疫苗研究

选用从国内浙江省某猪场流产死胎中分离的猪细小病毒强毒（简称浙PV－Z株），通过仔猪肾原代细胞增殖后，经甲醛灭活，再配以20％的氨氧化铝胶佐剂制成猪细小病毒氢氧化铝疫苗。该疫苗免疫性好，免疫程序简单。小剂量肌注豚鼠和猪，均能激起明显的抗体应答反应，疫苗对豚鼠接种2次HI价可达到1：320以上（通常1：640－1：1280）。对成年猪接种疫苗0．2ml,0.5ml,1.0ml免疫2次，或用2．0ml免疫1次，HI价范围在1：20－1：320之间，疫苗对胎儿的保护率可达到98．7％。实验室和田间跟踪试验显示该疫苗具有保存期长、耐热、安全、免疫保护率高等特点。     

非洲猪瘟形势下猪流行性腹泻的防控措施

自2018年第一例非洲猪瘟疫情报道至今已经两年多了。为了快速扩繁猪群,许多清空场及新建场不得不大量外购来源复杂后备猪进群。因此,猪场在对猪流行性腹泻的防控上面临着更大的挑战。文章介绍了病毒性腹泻暴发的原因、防控难点和综合防控措施,期望为养殖业同人在实际生产中,科学防控猪流行性腹泻提供一定的参考借鉴。     

非洲猪瘟疫苗研究的困境和展望

非洲猪瘟（ASF）目前是生猪产业最重要的猪病。因为非洲猪瘟病毒（ASFV）本身的复杂性,以及和宿主相互作用的复杂性导致ASF已经被报道一百年了,还没有商业化疫苗。理想的ASF疫苗不仅要有好的免疫保护性,更重要的是其安全性,同时如果能区分野毒感染和疫苗接种,能在适合的高质量GMP车间进行稳定低价的生产,能用于不同物种就更好了。ASF灭活疫苗研制这条道路似乎不通;亚单位疫苗、DNA疫苗、病毒活载体疫苗的免疫保护能力不足;主要包含自然缺失、传代致弱、基因工程缺失的减毒活疫苗在免疫保护方面体现了非常大的优势,但是其潜在的持续感染风险,会造成猪只的副作用,包括皮肤溃烂、关节炎,导致神经系统、呼吸系统的损伤等问题非常值得警惕。复制缺陷单周期病毒能有效地解决减毒活疫苗的安全性问题,似乎是一个值得尝试的ASF疫苗研制方向,尽管存在难以确定缺失复制相关的基因,以及难以构建能高效表达缺失基因编码蛋白,且能让单周期病毒稳定大量生产的辅助细胞系。我国针对ASFV强毒的精准剔除策略,未注册非法弱毒苗造成临床严重损失,以及一些不使用疫苗但成功从国家层面净化ASF的案例,让我们认识到针对ASF基础研究的重要性。同时至少目前阶段,ASF的防控不一定要借助疫苗,更多的要做好生物安全管控和区域ASF净化。尽管ASF疫苗研制困难重重,但针对ASF理想型疫苗的研制也应该持续进行下去,未来可能作为ASF防控的一个突破点。     

Poxviruses as vaccine vectors

The discovery of Jenner in 1798 founded the science of immunology and eventually led to smallpox eradication from the earth in 1980 after a world-wide vaccination campaign with vaccinia virus (another poxvirus) and paradoxically, despite the eradication of smallpox, there has been an explosion of interest in vaccinia virus in the eighties. This interest has stemmed in part from the application of molecular genetics to clone and express foreign genes from recombinant vaccinia viruses. Vaccinia is also gaining renewed interest due to bioterrorism.

These recombinant viruses have multiple applications in research and vaccinology and led to the development of vectored vaccines, such as the recombinant vaccinia rabies vaccine used to eliminate rabies in Western Europe and, more recently, in the United States. Secondly, alternative poxvirus vectors, such as avipox viruses, were proved to be even safer and efficacious non-replicating vectors (suiciole vectors) when used in non-avian species.     

Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy

Biological weapons are considered as mass destruction and terror weapons. Terrorism including bioterrorism is the major threat in the future conflicts for our nations. The aim of bioterrorism is more related to the potential disorganisation of the society than to the lethal effects of the agents used. The dramatic consequences cannot be discarded, especially if contagious agents such viral are used. The preparation of specific defence measures is a major challenge for our countries.

The knowledge acquired from the struggle against natural infectious diseases and recent events are essential to improve behaviours to face the biological weapon threats. The defence attitude is based on the anticipation of the threat, the management of the victims, and the restoration of the operational capabilities. This global defence attitude implies six important functions: (i) alert, (ii) detection and diagnosis, (iii) availability of pharmaceutical countermeasures such as vaccine, sera and anti-infectious medicine and products, (iv) medical management of victims, (v) training and information, (vi) research and development.

Passive and active immunoprevention and immuntherapy belong to the approaches discussed in the context of bioterrorism countermeasures. Further researches might be focused on these topics.     

Brucellosis in Argentina

Brucellosis has been recognized in Argentina since the 19th century. Several studies demonstrated the presence of the disease in most of the domestic species. Actually, the estimate of prevalence is that between 10 and 13% of the farm animals are infected with bovine brucellosis with an individual rate of 4–5%. The annual economical losses have been estimated at US$ 60,000,000. The control of bovine brucellosis began in 1932 and successive resolutions have been issued since then. The current resolution indicates that B. abortus S19 is mandatory in female calves between 3 and 8 months of age. The vaccine strain B. abortus RB51 was provisionally approved but only for cattle older than 10 months of age. The brucellosis control program consists principally of test and slaughter. This methodology has been successful mainly in the dairy farms that have the incentive due to increased pricing because of obtaining a low prevalence of the disease. Brucellosis has been found in porcine, caprine, ovine and canine species. All Brucella species have been found in the country. Human brucellosis is an important disease and a national coordinated diagnostic net has been formed to better control the disease in man.     

乙脑病毒PrME基因在杆状病毒表达系统中的表达

本试验将乙型脑炎病毒（ＪＥＶ）的ＰｒＭ／Ｅ基因的ＨｉｎｄⅢ－ＢｇｌⅡ片段（２．１ｋｂ）插入到杆状病毒载体ｐＡｃＵＷ３１的ＢａｍＨＩ位点,使外源基因置于多角体蛋白启动予下游,构建成转移载体ｐＡｃＵＷ３１ＪＥ,以Ｌｉｐｏｆｅｃｔｉｎ作为共转染试剂,将纯化的ｐＡｃＵＷ３１ＪＥ与Ｂｓｕ３６Ｉ线性化的杆状病毒ＡｃＭＮＰＶ．ＬａｃＺＤＮＡ共转染昆虫ｓｆ９经病毒蚀斑纯化技术和Ｘ－ｇａｌ与中性红双重染色技术,随机     

鸭传染性浆膜炎疫苗的研究

用从浙江省分离鉴定的鸭疫里氏杆菌RA-J、RA-L菌株研制疫苗，采用改进的液体培养和鸭胚培养工艺，抗原含量分别达120-186亿CFU／ml和280-310CFU／ml，免疫0.5ml/只，2MLD强毒攻击，平均保护率达94.2％（48／52），免疫后第7天保护率达80％（16／20），10天达93.8％（15／16），疫苗在4℃-8℃条件下保存7个半月和1年的保护率达90％和85％。野外扩大试验和临床推广试用236万羽份表明，效果良好。